Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy to prevent relapses in MOGAD, but existing reports are limited to the use of intravenous Ig (IVIG). Subcutaneous Ig (SCIG) may exhibit several advantages over IVIG, including self-administration and less systemic adverse effects. Herein, we report six patients with MOGAD who were treated with subcutaneous Ig (SCIG) with good tolerability and without any relapses during follow-up. This supports the rationale for prospective randomized studies of SCIG in MOGAD.
Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin
Mariotto, Sara;
2022-01-01
Abstract
Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy to prevent relapses in MOGAD, but existing reports are limited to the use of intravenous Ig (IVIG). Subcutaneous Ig (SCIG) may exhibit several advantages over IVIG, including self-administration and less systemic adverse effects. Herein, we report six patients with MOGAD who were treated with subcutaneous Ig (SCIG) with good tolerability and without any relapses during follow-up. This supports the rationale for prospective randomized studies of SCIG in MOGAD.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
